Free Trial
NASDAQ:QTTB

Q32 Bio Q2 2024 Earnings Report

Q32 Bio logo
$1.60 -0.04 (-2.44%)
As of 12:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Q32 Bio EPS Results

Actual EPS
-$1.42
Consensus EPS
-$1.00
Beat/Miss
Missed by -$0.42
One Year Ago EPS
N/A

Q32 Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Q32 Bio Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:15AM ET

Upcoming Earnings

Q32 Bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Q32 Bio Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
See More Q32 Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email.

About Q32 Bio

Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

View Q32 Bio Profile

More Earnings Resources from MarketBeat